Hearing in adults with Pompe disease

Journal of Inherited Metabolic Disease

Volumn 35, Issue 2, 2012, Pages 335-341

  Van Der Beek, Nadine A M E ^a,b   Verschuure, Hans ^a   Reuser, Arnold J J ^a   Van Der Ploeg, Ans T ^b   Van Doorn, Pieter A ^a   Poublon, René M L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AIR CONDUCTION; ARTICLE; AUDITORY SYSTEM EXAMINATION; AUDITORY THRESHOLD; BONE CONDUCTION; CLINICAL ARTICLE; CONDUCTION DEAFNESS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT; GLYCOGEN STORAGE DISEASE TYPE 2; HEARING LOSS; HUMAN; MALE; MIDDLE EAR DISEASE; PERCEPTION DEAFNESS; PREVALENCE; PURE TONE AUDIOMETRY; TYMPANOMETRY;

ACOUSTIC IMPEDANCE TESTS; ADULT; AGED; ALPHA-GLUCOSIDASES; AUDIOMETRY, PURE-TONE; AUDITORY THRESHOLD; COHORT STUDIES; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HEARING LOSS, SENSORINEURAL; HUMANS; MALE; MIDDLE AGED;

EID: 84863445511     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-011-9396-3     Document Type: Article

References (32)

1. Amalfitano A, Bengur AR, Morse RP et al. (2001) Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 3:132-138
2. Bamiou DE, Campbell P, Liasis A et al. (2001) Audiometric abnormalities in children with Gaucher disease type 3. Neuro- pediatrics 32:136-141
3. Campbell PE, Harris CM, Harris CM, Sirimanna T, Vellodi A (2003) A model of neuronopathic Gaucher disease. J Inherit Metab Dis 26:629-639
4. Chakrapani A, Vellodi A, Robinson P, Jones S, Wraith JE (2010) Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience. J Inherit Metab Dis 33:747-750
5. Davis AC (1989) The prevalence ofhearing impairment and reported hearing disability among adults in Great Britain. Int J Epidemiol 18:911-917
6. Hegemann S, Hajioff D, Conti G et al. (2006) Hearing loss in Fabry disease: data from the Fabry Outcome Survey. Eur J Clin Invest 36:654-662
7. Hirschhorn R, Reuser A (2001) Glycogen storage disease type II: acid a- glucosidase (acid maltase) deficiency In: Scriver CR, Beaudet AL, Sly W, Valle D (eds) The metabolic and molecular bases ofinherited disease. McGraw-Hill, New York, pp 3389-3420
8. International Organization for Standardization (1989) Acoustics - Audiometric test methods - Part 1: Basic pure tone air and bone conduction threshold audiometry. ISO 8253-1
9. International Organization for Standardization (2000) Acoustics - statistical distribution of hearing thresholds as a function of age, ISO 7029
10. Johansson MS, Arlinger SD (2003) Prevalence of hearing impairment in a population in Sweden. Int J Audiol 42:18-28
11. Kamphoven JH, de Ruiter MM, Winkel LP et al. (2004) Hearing loss in infantile Pompe's disease and determination of underlying pathologyin the knockout mouse. Neurobiol Dis 16:14-20
12. Keilmann A, Hajioff D, Ramaswami U (2009) Ear symptoms in children with Fabry disease: data from the Fabry Outcome Survey. J Inherit Metab Dis 32:739-744
13. Kishnani PS, Nicolino M, Voit T et al. (2006) Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 149:89-97
14. Kishnani PS, Corzo D, Nicolino M et al. (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68:99-109
15. Klinge L, Straub V, Neudorf U, Voit T (2005) Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study. Neuropediatrics 36:6-11
16. Komura Y, Kaga K, Ogawa Y, Yamaguchi Y, Tsuzuku T, Suzuki JI (1998) ABR and temporal bone pathology in Hurler's disease. Int J Pediatr Otorhinolaryngol 43:179-188
17. Laforêt P, Nicolino M, Eymard B et al. (2000) Juvenile and adult- onset acid maltase deficiency in France. Genotype-phenotype correlation. Neurology 55:1122-1128
18. Müller-Felber W, Horvath R, Gempel K et al. (2007) Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuro- muscul Disord 17:698-706
19. Peck JE (1984) Hearing loss in Hunter's syndrome-mucopolysaccharidosis II. Ear Hear 5:243-246
20. Rohrbach M, Klein A, Kohli-Wiesner A et al. (2010) CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis 33:751-757
21. Schachern PA, Shea DA, Paparella MM, Yoon TH (1989) Otologic histopathology of Fabry's disease. Ann Otol Rhinol Laryngol 98:359-363
22. Schoser BG, Muller-Hocker J, Horvath R et al. (2007) Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited. Neuropathol Appl Neurobiol 33:544-559
23. Strothotte S, Strigl-Pill N, Grunert B et al. (2009) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol
24. van Capelle CI, Goedegebure A, Homans NC, Hoeve HL, Reuser AJ, van der Ploeg AT (2010a) Hearing loss in Pompe disease revisited: results from a study of24 children. J Inherit Metab Dis 33:597-602
25. van Capelle CI, van der Beek NA, Hagemans ML et al. (2010b) Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study. Neuromuscul Disord 20:775-782
26. van den Hout JM, Reuser AJ, de Klerk JB, Arts WF, Smeitink JA, van der Ploeg AT (2001) Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis 24:266-274
27. van der Ploeg AT, Reuser AJ (2008) Pompe's disease. Lancet 372:1342-1353
28. van der Ploeg AT, Clemens PR, Corzo D et al. (2010) A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 362:1396-1406
29. Wilson DH, Walsh PG, Sanchez L et al. (1999) The epidemiology of hearing impairment in an Australian adult population. Int J Epidemiol 28:247-252
30. Winkel LP, Van den Hout JM, Kamphoven JH et al. (2004) Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol 55:495-502
31. Wokke JHJ, Escolar DM, Pestronk A et al. (2008) Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve 38:1236-1245
32. World Health Organization (2001) International classification of functioning, disability and health. WHO, Geneva